[Pulmonary lymphangioleiomyomatosis: From pathogenesis to management]

Abstract

Introduction: Pulmonary lymphangioleiomyomatosis (LAM) is a rare disease affecting mainly young women.

Background: The respiratory manifestations are characterized by a progressive cystic destruction of the lung parenchyma. Extrapulmonary involvement includes benign renal tumours called angiomyolipomas and abdominal lymphatic masses called lymphangioleiomyomas. At the pathological level, the cellular proliferation found in LAM is in part due to the presence of mutations in the tumour suppressor genes TSC1 and TSC2 (Tuberous Sclerosis Complex). These mutations lead to the activation of the mTOR pathway, which is currently the main therapeutic target. mTOR inhibitors such as sirolimus or everolimus have shown a beneficial effect on the decline in pulmonary function and a reduction of angiomyolipoma size, but are necessary in only some patients.

Perspectives: LAM cells have migratory properties mediated by the formation of new lymphatic vessels. They are also able to secrete metalloproteases, which enhance their invasiveness. Moreover, the expression of estrogen and progesterone receptors by LAM cells suggests a possible role for sex hormones in the pathogenesis of the disease.

Conclusion: A better understanding of mTOR-independent mechanisms would allow the development of novel therapeutic approaches.

Keywords: Angiomyolipoma; Angiomyolipome; Lymphangioleiomyomatosis; Lymphangioléiomyomatose; MTOR protein; Protéine mTOR; Sclérose tubéreuse de Bourneville; Sirolimus; Tuberous sclerosis.